Abstract
Intraoperative blood loss requiring allogenic blood transfusion (ABT) is a common problem in major orthopedic surgery. Since transfusion related side effects up to fatal consequences due to blood type incompatibility cannot be excluded completely, it is desirable to reduce the amount of blood loss and transfusions to a minimum. Encouraging results in the application of aprotinin, a natural protease-inhibitor with antifibrinolytic, bleeding-reducing properties, in thoracic-, heart- and abdominal surgery led to the use of aprotinin also in orthopedic surgery. One important safety issue in the use of aprotinin in orthopedic surgery is a possible negative effect on the osseous integration of an implant due to the multiple interactions of aprotinin with several enzymatic systems. In this study, we therefore investigated the influence of aprotinin on the osseous ingrowth of a titanium-implant in a rat model. Forty female Sprague–Dawley rats underwent unilateral retrograde nailing of the femur. Animals were divided in two groups, one receiving i.v. aprotinin intraoperatively, the other group receiving the same amount as saline solution. After 56 days animals were killed and from each group half of the femora were prepared for biomechanical testing, the other half for histological examination. The push-out experiment revealed no significant difference between the aprotinin-group and the control-group, both showing comparable shear stresses. In addition, the histomorphometrical analysis showed comparable implant integration between both groups. The results demonstrate that perioperative aprotinin application has no negative effect on osseous implant integration in a rat model.
Similar content being viewed by others
References
Beierlein W, Scheule AM, Dietrich W, Ziemer G (2005) Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 79(2):741–748
Bethge JF, Babayan R, Borm HP, von Fehrentheil R, ten Hoff H, Hose H, Mangels P, Piening H, Reimers C, Wider U (1979) Experimental acceleration of fracture repair by biochemical media. Res Exp Med (Berl) 175(3):197–222
Brown JR, Birkmeyer NJ, O’Connor GT (2007) Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115(22):2801–2813
Clasen C, Jochum M, Mueller-Ester1 W (1987) Feasibility study of very high dose aprotinin in polytrauma patients. In: Schlag G, Red1 H (eds) First Vienna Shock Forum. Pathophysiological role of mediators and mediator inhibitors in shock. Liss, New York, pp 175–183
Engles L (2005) Review and application of serine protease inhibition in coronary artery bypass graft surgery. Am J Health Syst Pharm 62:S9–14
Fiebig E (1998) Safety of the blood supply. Clin Orthop 357:6–18
Frost A, Jonsson KB, Ridefelt P, Nilsson O, Ljunghall S, Ljungren O (1999) Thrombin, but not bradykinin, stimulates proliferation in isolated human osteoblasts, via a mechanism not dependent on endogenous prostaglandin formation. Acta Orthop Scand 70(5):497–503
Hunter D (2006) First gather the data. N Engl J Med 354(4):329–331
Innerhofer P, Walleczek C, Luz G, Hobisch-Hagen P, Benzer A, Stockl B, Hessenberger G, Nussbaumer W, Schobersberger W (1999) Transfusion of buffy coat-depleted blood components and risk of postoperative infection in orthopedic patients. Transfusion 39(6):625–632
Kokoszka A, Kuflik P, Bitan F, Casden A, Neuwirth M (2005) Evidence-based review of the role of aprotinin in blood conservation during orthopaedic surgery. J Bone Joint Surg Am 87(5):1129–1136
Krishnan LK, Vijayan Al A, Uma Shankar PR, Mohanty M (2003) Fibrinolysis inhibitors adversely affect remodeling of tissues sealed with fibrin glue. Biomaterials 24(2):321–327
Lerner UH (1994) Regulation of bone metabolism by the kallikrein–kinin system, the coagulation cascade, and the acute-phase reactants. Oral Surg Oral Med Oral Pathol 78(4):481–493
Lerner UH, Gustafson GT (1988) Blood coagulation and bone metabolism: some characteristics of the bone resorptive effect of thrombin in mouse calvarial bones in vitro. Biochim Biophys Acta 964(3):309–318
Levy JH, Despotis GJ, Spitznagel E (2006) Should aprotinin continue to be used during cardiac surgery? Nat Clin Pract Cardiovasc Med 3(7):360–361
Levy JH, Sypniewski E (2004) Aprotinin: a pharmacologic overview. Orthopedics 27(6 Suppl):s653–658 (review)
Lien M, Milbrandt EB (2006) A disheartening story: aprotinin in cardiac surgery. Crit Care 10(6):317
Mangano DT, Tudor IC, Dietzel C (2006) Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation: The risk associated with aprotinin in cardiac surgery. N Engl J Med 354(4):353–365
Murkin JM, Haig GM, Beer KJ, Cicutti N, McCutchen J, Comunale ME, Hall R, Ruzicka BB (2000) Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am 82:675–684
Murphy P, Heal JM, Blumberg N (1991) Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion 31(3):212–217
Pagel CN, Sivagurunathan S, Loh LH, Tudor EM, Pike RN, Mackie EJ (2006) Functional responses of bone cells to thrombin. Biol Chem 387(8):1037–1041
Pagel CN, de Niese MR, Abraham LA, Chinni C, Song SJ, Pike RN, Mackie EJ (2003) Inhibition of osteoblast apoptosis by thrombin. Bone 33(4):733–43; Erratum in Bone 2004 July; 35(1):343
Pintigny D, Dachary-Pregent J (1992) Aprotinin can inhibit the proteolytic activity of thrombin. A fluorescence and an enzymatic study. Eur J Biochem 207(1):89–95
Ray M, Hatcher S, Whitehouse SL, Crawford S, Crawford R (2005) Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty—a prospective randomized double-blind placebo-controlled study. J Thromb Haemost 3:1421–1427
Royston D (1992) High-dose aprotinin therapy: a review of the first five years’ experience. J Cardiothorac Vasc Anesth 6(1):76–100
Royston D, Taylor KM, Bidstrup BP, Sapsford RN (1987) Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 2:1289–1291
Schmidmaier G, Wildemann B, Schwabe P, Stange R, Hoffmann J, Sudkamp NP, Haas NP, Raschke M (2002) A new electrochemically graded hydroxyapatite coating for osteosynthetic implants promotes implant osteointegration in a rat model. J Biomed Mater Res 63:168–172
Shiga T, Wajima Z, Inoue T, Sakamoto A (2005) Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials. Anesth Analg 101(6):1602–1607
Smith PK, Muhlbaier LH (1996) Aprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg 62:1575–1577
Vanek T, Jares M, Fajt R, Straka Z, Jirasek K, Kolesar M, Brucek P, Maly M (2005) Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). Eur J Cardiothorac Surg 28:563–568
Acknowledgments
We would like to thank Bayer HealthCare Germany for supporting this study.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s00402-008-0604-z
Rights and permissions
About this article
Cite this article
Faensen, B., Hain, C., Höhne, J. et al. Aprotinin application has no negative effect on osseous implant integration: a biomechanical and histomorphometric investigation in a rat model. Arch Orthop Trauma Surg 129, 51–56 (2009). https://doi.org/10.1007/s00402-008-0582-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00402-008-0582-1